Mechanism Of Smell Loss During COVID Reveals A Hidden Trigger
- 01. What actually causes smell loss during COVID-19?
- 02. Anatomy and physiology of smell
- 03. Viral entry and early infection in the nose
- 04. Acute inflammation and immune signaling
- 05. From acute to persistent smell loss
- 06. Key mechanisms at a glance (timeline)
- 07. Table: Mechanisms of smell loss in COVID-19
- 08. What did scientists "miss" early on?
- 09. Variants and changing patterns of smell loss
- 10. Diagnosis and assessment of smell loss
- 11. Treatment approaches and emerging therapies
- 12. Taking stock: what the science now suggests
What actually causes smell loss during COVID-19?
During acute COVID-19 infection, loss of smell (anosmia) is thought to occur mainly because the SARS-CoV-2 virus infects non-neuronal sustentacular cells in the olfactory epithelium, triggering local inflammation and disrupting the support bed that olfactory sensory neurons depend on, rather than destroying the smell nerves themselves outright. In persistent post-COVID smell loss, emerging evidence points to a lingering T-cell-mediated immune response in the nose that continues to damage or silence olfactory sensory neurons even after the virus is gone, resembling a low-grade autoimmune-like process in the nasal lining.
Anatomy and physiology of smell
The human olfaction system starts in the nasal cavity, where odor-bearing molecules bind to receptors on the cilia of olfactory receptor neurons embedded in the olfactory neuroepithelium at the top of the nasal passage. These neurons send axons through the cribriform plate of the skull into the olfactory bulb, which then relays information to the olfactory cortex and limbic regions involved in emotion and memory.
Adjacent to these neurons lie sustentacular cells, which provide structural support, help regulate the mucus layer, and supply metabolic substrates such as glucose that are critical for normal olfactory signal transduction. When this support system is perturbed, the neurons can become functionally silent or structurally damaged, even if the olfactory nerve fibers themselves are not directly infected.
Viral entry and early infection in the nose
SARS-CoV-2 gains entry into host cells via the ACE2 receptor and the TMPRSS2 protease, both of which are highly expressed in respiratory epithelial cells but relatively sparse in mature olfactory sensory neurons. Instead, sustentacular cells and other non-neuronal cells in the olfactory epithelium show abundant ACE2/TMPRSS2 expression, making them the primary viral targets in the nasal lining.
When these support cells are infected, they can undergo cell death or dysfunction, leading to collapse of the local microenvironment that maintains the delicate cilia and dendrites of the olfactory neurons. This disruption helps explain why many patients experience a sudden, near-total anosmia within a day or two of infection, often before significant nasal congestion sets in.
Acute inflammation and immune signaling
The presence of SARS-CoV-2 in sustentacular cells triggers an innate immune response, including the release of cytokines such as interferon-γ and recruitment of immune cells into the olfactory epithelium. This acute inflammation can alter gene expression in both support cells and nearby olfactory receptor neurons, downregulating key genes involved in olfactory signal transduction and reducing the electrical responsiveness of the neurons.
Several studies estimate that roughly 50-80% of COVID-19 patients experience some degree of olfactory dysfunction during the first pandemic waves, with nearly half reporting it as an early or even isolated symptom. In many of these cases, the dysfunction is transient and resolves within **1-3 months** as the infected sustentacular cells regenerate and the inflammatory milieu subsides.
From acute to persistent smell loss
For a subset of patients-studies suggest about **10-20% of those with initial anosmia**-smell does not return to baseline and instead evolves into persistent post-COVID dysosmia, which can last months or years. Nasal biopsy work led by Duke Health and collaborators, published in Science Translational Medicine in December 2022, showed that these patients have dense infiltration of T cells and altered myeloid populations in the olfactory epithelium, even when SARS-CoV-2 RNA or protein is no longer detectable.
This ongoing T-cell-mediated inflammation appears to suppress the activity of surviving olfactory sensory neurons, reducing the number of cells that express functional olfactory receptors. At the same time, the ratio of olfactory neurons to sustentacular cells diminishes, suggesting a cellular imbalance that may underlie chronic anosmia or parosmia (distorted smell).
Key mechanisms at a glance (timeline)
- Days 0-3 after infection: Virus enters nasal epithelium; sustentacular cells become infected and begin to malfunction, often before major congestion.
- Days 3-7: Acute inflammation in the olfactory epithelium; cytokines and immune signaling silence or damage olfactory receptor neurons.
- Weeks 1-3: For most patients, support cells regenerate and inflammation resolves, allowing partial or full smell recovery.
- Months 3-12+: In a minority, persistent T-cell infiltration and altered gene expression maintain a low-grade inflammatory state, leading to long-term anosmia.
Table: Mechanisms of smell loss in COVID-19
| Mechanism type | Primary site | Cellular players | Typical duration | Approx. patient share of cases |
|---|---|---|---|---|
| Support-cell disruption | Olfactory epithelium | Sustentacular cells, mucus layer | Days to weeks | Majority of early anosmia (~60-70%) |
| Acute inflammation | Nasal mucosa | Macrophages, cytokines (IFN-γ), dendritic cells | 1-4 weeks | Very common (~80% of symptomatic) |
| T-cell-mediated persistence | Olfactory epithelium | T cells, altered myeloid cells | Months to years | Approx. 10-20% of anosmia patients |
| Neuronal or central damage | Olfactory bulb / cortex | Neurons, glia, cortical circuits | Unknown, often chronic | Smaller subset, still under study |
What did scientists "miss" early on?
Early in the pandemic, many clinicians and researchers assumed that COVID-19 smell loss was simply a form of classic post-viral anosmia, where physical damage to the olfactory neurons or nasal blockage explained slow recovery. However, detailed biopsy and single-cell sequencing work, particularly the 2022 Duke-Harvard collaboration, revealed that the nerves themselves were often not destroyed, but rather suppressed by a chronic, targeted immune response.
"We found widespread T-cell infiltration in the olfactory epithelium despite the absence of detectable SARS-CoV-2," lead author **Bradley Goldstein** noted in the Science Translational Medicine paper, "which is striking and suggests an autoimmune-like process."This reframing shifted the focus from mere nerve regeneration to modulating the nasal immune microenvironment as a therapeutic strategy.
Variants and changing patterns of smell loss
With the emergence of the Omicron variant in late 2021, the epidemiology of COVID-19-related anosmia changed noticeably. Population-based surveys suggest that the incidence of acute smell loss dropped from around **40-70%** in early Alpha/Delta waves to roughly **15-25%** with Omicron, while overall case counts rose.
Researchers attribute this partly to Omicron's preference for upper-airway replication and a different balance of ACE2/TMPRSS2 usage, which may spare the olfactory epithelium more than earlier variants. Nonetheless, a subset of Omicron-infected patients still develop persistent dysosmia, indicating that the underlying immune mechanisms can persist even as acute symptoms become milder.
Diagnosis and assessment of smell loss
When evaluating post-COVID smell loss, clinicians typically begin with a structured history and examination of nasal anatomy, ruling out mechanical obstruction such as nasal polyps or chronic rhinosinusitis. Objective tools like the Sniffin' Sticks test or UPSIT (University of Pennsylvania Smell Identification Test) quantify anosmia, hyposmia, or parosmia with standardized odor-identification panels.
- First step: Confirm timing relative to COVID-19 and document onset, severity, and progression.
- Second step: Perform a nasal endoscopy to assess nasal patency and mucosal appearance.
- Third step: Apply a validated smell-test battery to classify dysfunction type.
- Fourth step: Consider MRI of the olfactory bulb and tracts if central pathology is suspected.
- Fifth step: For persistent cases, discuss referral for smell-training programs or enrollment in Long COVID research cohorts.
Treatment approaches and emerging therapies
For acute anosmia, most guidelines emphasize conservative management: hydration, gentle nasal care, and monitoring, since the majority recover spontaneously within a few months. In some series, about **80% of patients** who lose smell with COVID-19 regain normal or near-normal function within **1-3 months**, though subtle deficits may linger.
For persistent smell loss, the two main pillars are:
- Smell training (olfactory training): Repeated exposure to a set of strong odorants such as eucalyptus, rose, lemon, and clove twice daily, which may promote neuroplasticity in the olfactory bulb and cortex.
- Anti-inflammatory strategies: Experimental use of intranasal corticosteroids, leukotriene modifiers, or other immunomodulators to dampen the T-cell-rich infiltrate observed in biopsies.
Taking stock: what the science now suggests
The current weight of evidence indicates that COVID-19 smell loss operates through a cascade: SARS-CoV-2 infection of sustentacular cells, acute local inflammation, temporary silencing of olfactory neurons, and, in a subset of patients, a chronic T-cell-driven immune attack that maintains dysfunction. This framework explains both the rapid onset and relative reversibility in many cases, as well as the stubborn persistence in others, and it has opened new avenues for targeted therapies that move beyond simple "wait and see" approaches.
Helpful tips and tricks for Mechanism Of Smell Loss During Covid Reveals A Hidden Trigger
Is loss of smell a sign of permanent nerve damage?
Most data now suggest that olfactory sensory neurons themselves are often not destroyed in post-COVID anosmia, especially in cases lasting less than a few months. Instead, the functional loss usually reflects temporary inflammation or immune-mediated suppression of these neurons, which can recover as the olfactory epithelium heals and inflammatory signals decline.
Why does smell sometimes come back distorted (parosmia)?
Parosmia-the perception of smells as foul, burnt, or chemically altered-is thought to arise when regenerating olfactory receptor neurons or recovering neuronal circuits miscode odor signals in the olfactory bulb and cortex. This distortion is often a transitional phase, seen in roughly **20-30% of patients** who initially report anosmia, with many gradually improving over months as patterns of activity normalize.
Could smell loss point to brain-related complications?
While most COVID-19 smell loss is peripheral (originating in the olfactory epithelium or bulb), a minority of patients show changes in the olfactory cortex or related brain regions on imaging, likely from local inflammation or viral effects. However, there is no strong evidence that typical anosmia by itself predicts future dementia or major neurodegeneration; current concern centers instead on the broader constellation of Long COVID neurological symptoms.
How common is persistent smell loss now?
Among patients who had anosmia during acute infection, recent cohort studies estimate that **roughly 10-20%** continue to report significant persistent smell dysfunction** a year or more later, even if their infection was mild. This group contributes to the growing burden of Long COVID-related smell disorders, which has driven the expansion of specialized smell-dysfunction clinics and NIH-funded research programs.